COMMUNIQUÉS West-GlobeNewswire

-
RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call
20/10/2025 -
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
20/10/2025 -
WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members
20/10/2025 -
BioCryst to Report Third Quarter 2025 Financial Results on November 3
20/10/2025 -
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/10/2025 -
J-Star Applauds the Cooperation of Nasdaq and Ho Chi Minh City to Develop an International Financial Center in Vietnam
20/10/2025 -
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
20/10/2025 -
Medicenna Therapeutics Announces Participation in Upcoming Conferences
20/10/2025 -
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
20/10/2025 -
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
20/10/2025 -
Humber River Health Celebrates 10-Year Anniversary of Wilson Site
20/10/2025 -
Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard
20/10/2025 -
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
20/10/2025 -
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
20/10/2025 -
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
20/10/2025 -
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
20/10/2025 -
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
20/10/2025 -
Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...)
20/10/2025 -
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20/10/2025
Pages